Title: Drug Price Transparency Act
Policy area: Health

Summary:
Drug Price Transparency Act
This bill requires the Centers for Medicare & Medicaid Services to report on the feasibility of basing payment rates for prescription drugs under Medicare and Medicare Advantage on the average price of such drugs in countries that are members of the Organization for Economic Cooperation and Development (an intergovernmental organization focused on global economic development).

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 6958 Introduced in House (IH)]

<DOC>






115th CONGRESS
  2d Session
                                H. R. 6958

    To provide for a study and report on the feasibility of basing 
reimbursement rates for Medicare part B drugs and covered part D drugs 
   on the average prices for such drugs in the member-states of the 
         Organization for Economic Cooperation and Development.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           September 27, 2018

 Mr. Francis Rooney of Florida (for himself and Mr. Welch) introduced 
 the following bill; which was referred to the Committee on Energy and 
  Commerce, and in addition to the Committee on Ways and Means, for a 
 period to be subsequently determined by the Speaker, in each case for 
consideration of such provisions as fall within the jurisdiction of the 
                          committee concerned

_______________________________________________________________________

                                 A BILL


 
    To provide for a study and report on the feasibility of basing 
reimbursement rates for Medicare part B drugs and covered part D drugs 
   on the average prices for such drugs in the member-states of the 
         Organization for Economic Cooperation and Development.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Drug Price Transparency Act''.

SEC. 2. STUDY AND REPORT ON FEASIBILITY OF BASING REIMBURSEMENT RATES 
              FOR MEDICARE PART B DRUGS AND COVERED PART D DRUGS ON 
              AVERAGE PRICES FOR SUCH DRUGS IN OECD MEMBER STATES.

    From amounts otherwise made available to the Secretary of Health 
and Human Services, the Secretary shall use not to exceed $100,000 of 
such amounts to, not later than 90 days after the date of the enactment 
of this Act, conduct a study, and submit to Congress a report, on the 
feasibility of--
            (1) basing reimbursement rates under part B of the Medicare 
        program under title XVIII of the Social Security Act for 
        prescription drugs for which coverage is provided under part B 
        of the Medicare program on the average price of such drugs in 
        the member-states of the Organization for Economic Cooperation 
        and Development; and
            (2) basing payment rates under prescription drug plans 
        under part D of such title (and under MA-PD plans under part C 
        of such title) for covered part D drugs (as defined in section 
        1860D-2(e) of such Act (42 U.S.C. 1395w-102(e))) on the average 
        price of such drugs in such member-states.
                                 <all>